Triveni Bio has dosed the first healthy volunteers in its Phase I study of TRIV-573, a half-life extended bispecific antibody aimed at KLK5/7 and IL-13.

If Protara secures approval for TARA-002 in NMIBC, it would become the first drug in its class to get the regulatory greenlight.

At ASCO 2026, AstraZeneca will release the first results from its first-in-human, open-label Phase I/II trial, PRIMAVERA (NCT06137144).

MSD said that TroFuse-005 is the first global Phase III trial to demonstrate statistically significant improvement in both OS and PFS compared to chemotherapy for these patients and the first and only ...

Ipsen has announced Phase II corabotase data in glabellar lines, reporting sustained duration of effect and consistently high patient satisfaction.

Regeneron Pharmaceuticals has reported that its Phase III trial assessing fianlimab and cemiplimab for metastatic melanoma failed to reach statistical significance for the primary endpoint.

While Vincentage's study will only support approval of the oral GLP-1RA in China, the drug is in a Phase II trial in the US.

Biogen and Ionis' anti-tau therapy demonstrated the strongest efficacy signal at the low 60mg Q6M dose in Alzheimer's disease.

As rheumatologists prepare for EULAR 2026, Clinical Trials Arena takes a look at the most promising drugs in late-stage development for PsA.

Shionogi's zatolmilast demonstrated an efficacy signal in one FXS study in adults, but it missed its primary endpoints across the programme.

This new high dose Wegovy data could help support Novo Nordisk in its bid to claw back market share taken by Eli Lilly in the obesity space.

Massive Bio has signed a strategic partnership with Just Worldwide to connect more cancer patients to clinical studies.